[Clinical Progress and Prospects of Antibody-drug Conjugates in Advanced NSCLC]
Yuling Zhong1,2, Jingyi Wang1, Lin Wu1
1The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Abstract:
Advances in targeted therapy and immunotherapy have significantly improved clinical outcomes for patients with advanced non-small cell lung cancer (NSCLC), reshaping treatment paradigms. However, most patients ultimately face drug resistance, with limited options for subsequent therapies and suboptimal treatment efficacy, presenting a prominent challenge in current clinical practice. Antibody-drug conjugates (ADCs), characterized by high efficacy and favorable safety profiles, have emerged as a promising therapeutic frontier in recent years. This systematic review provides a comprehensive overview of the latest advancements in ADCs-based therapies for lung cancer, alongside discussions of the prevailing challenges in this rapidly evolving domain. .
Insights
Antibody-drug conjugates (ADCs) offer a promising new approach for treating advanced non-small cell lung cancer (NSCLC) after initial therapies fail. This review highlights recent ADC advancements and challenges in NSCLC treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Targeted therapy and immunotherapy have improved outcomes for advanced non-small cell lung cancer (NSCLC).
- Drug resistance remains a significant challenge, limiting treatment options and efficacy for many NSCLC patients.
- Antibody-drug conjugates (ADCs) show promise due to their efficacy and safety.
Purpose of the Study:
- To provide a comprehensive overview of recent advancements in antibody-drug conjugate (ADC)-based therapies for lung cancer.
- To discuss current challenges and future directions in ADC development for NSCLC.
Main Methods:
- Systematic review of the latest research on ADCs in lung cancer treatment.
- Analysis of clinical outcomes, efficacy, and safety profiles of ADC therapies.
- Identification and discussion of challenges associated with ADC resistance and administration.
Main Results:
- ADCs represent a significant advancement in treating advanced NSCLC, offering new therapeutic options.
- Recent studies demonstrate the potential of ADCs to overcome resistance to prior treatments.
- Ongoing research focuses on optimizing ADC design and overcoming resistance mechanisms.
Conclusions:
- ADCs are emerging as a vital therapeutic strategy for advanced NSCLC, particularly in cases of drug resistance.
- Further research is needed to fully elucidate resistance mechanisms and optimize ADC efficacy.
- ADCs hold significant promise for improving patient outcomes in NSCLC treatment.
